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Abstract: At a 2010 Respiratory Symposium in Paris, chaired by Professors Bousquet and 
Roche of the University of Paris, recent trends in research, therapy and treatment guidelines 
for asthma and chronic obstructive pulmonary disease (COPD) were reviewed and discussed 
by a faculty of expert European and US respiratory physicians. This article reviews five key 
clinical presentations with particular emphasis given to the importance of small airways in the 
pathology and treatment of asthma and COPD. Further analysis of the economics of treatment 
in Europe and the US shows a wide variance in direct and indirect costs.
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Introduction
At the 2010 Teva Respiratory Symposium in Paris, chaired by Professors Bousquet 
and Roche of the University of Paris, recent trends in research, therapy and treatment 
guidelines for asthma and chronic obstructive pulmonary disease were reviewed and dis-
cussed by a faculty of expert European and US Respiratory physicians and an audience 
of general practice respiratory specialists. Professor Bousquet reminded the delegates 
that respiratory diseases, in global healthcare terms, are among the greatest challenges 
facing the medical world; the future potential economic cost of these diseases and their 
treatment is almost incalculable in scale, and the importance of correctly evaluating and 
selecting appropriate treatment strategies must not be underestimated.
Current guidelines may, as eminent expert commentators have recently said, be 
based on too narrow a view of evidence. Recognition of the greater importance of small 
airways in the mechanisms of respiratory diseases than previously understood, and the 
consequences for effective therapy, was a common topic in the presentations and work-
shops. True effectiveness of treatment outcomes delivered in clinical practice, rather 
than in the narrow focus of randomized, controlled clinical trials (RCTs), is a key issue 
impacting on choice of therapy, economic benefit and the development of improved 
inhaled therapy technologies. The scope and utility of different approaches to clinical 
assessment and reporting in published trials and investigations was a well-received topic, 
as the relevance of RCT evidence in isolation to outcomes in real-life clinical practice 
is increasingly under question. A summary of each presentation follows.
Treating all the airways
Professor r Dahl, Aarhus University Hospital, Denmark
The importance of small airways in the pathology and treatment of asthma has been 
underestimated in the past. Historically, there are a number of practical reasons for Journal of Asthma and Allergy 2011:4 submit your manuscript | www.dovepress.com
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this; health providers like to have a simple basis to   measure 
the success of treatment strategies; measuring forced 
expiratory volume in 1 second (FEV1), which is a simple 
  procedure, has been the standard applied to judge the success 
of treatment in respiratory conditions such as asthma and 
chronic obstructive pulmonary disease (COPD). A critical 
examination of the validity of FEV1 reveals, however, that it 
has a poor correlation with health outcomes, though various 
statistical techniques have been used to manipulate the data 
to demonstrate otherwise.
Conventionally, the airways are divided into large (lumen 
diameter .2 mm) and small (lumen diameter ,2 mm). This 
is an entirely arbitrary measurement, which was chosen 
simply because the original investigators had a minimum 
catheter size of 2 mm, so could not go any further than the 
first 7 divisions – there are in fact 14 to 17 more branch 
generations after 2 mm. Measurement of the small airways 
is difficult, since after each division the lumen decreases 
in diameter to 0.69 of the previous branch, FEV1 has been 
favored because it is relatively easy to measure; however, 
it primarily measures effects on the large central airways, 
those with a lumen diameter of .2 mm. Examination of the 
pathology in disease conditions such as bronchial asthma and 
COPD shows that the changes are much greater in the small 
airways (,2 mm diameter), with thickening of the lumen, 
much more mucus in the lumen, and more inflammatory 
changes. Whereas the inflammation in the large airways is 
inside the smooth muscle layer, close to the lumen, in the 
small airways it is much more in the outer circumference, 
which makes them more freely moveable, and so vulnerable 
to total collapse.
In COPD the same difference is found – thickening of 
the peripheral airways with smooth muscle hypertrophy 
and chronic airways inflammation. In COPD there are also 
emphysematous changes; the mucus increases resistance to 
airflow, there is goblet cell and gland hypertrophy, a remodel-
ing of the airways with smooth muscle hypertrophy, whereas 
in asthma the alveoli themselves are not so involved, and in 
COPD they seem to gradually disappear without an obvious 
explanation.1,2
In a study of airway obstruction in pulmonary disease, in 
normal subjects, the ratio of peripheral resistance (Rp) to total 
lung resistance was 0.24 during inspiration.3 Patients with 
bronchial asthma without airflow obstruction showed values 
of central resistance (Rc) and Rp similar to those of normal 
subjects. Rp but not Rc significantly increased in patients 
with bronchial asthma with obstruction and in COPD. 
This implies that peripheral airways are the   predominant 
site of airflow obstruction, irrespective of chronic airflow 
obstruction pathogenesis.
The question of effective treatment of asthma and COPD 
therefore needs to be examined with reference to the compo-
sition of the lungs as described, and to the distribution of the 
pathology. Considering inhalers, 3 groups of factors affect 
the deposition: device factors such as actuation method, 
resistance, and plume speed; patient factors such as inhalation 
technique, inspired volume and flow, breath hold pause, and 
airways disease type and severity; and formulation charac-
teristics – particle size, density, charge, and hygroscopicity. 
If we want to treat the whole of the airways using inhalers, 
there are clearly issues with particle size, as larger particles 
may not penetrate the smallest airways easily, where most of 
the pathology is to be found.
Studies have shown that the peripheral distribution is 
affected by speed of inhalation; rapid inhalation tends to lead 
to early deposition of drug in the oropharynx or large airways, 
with correspondingly less available to penetrate the small 
airways. So not only does total lung deposition vary with 
the content of the inhaler4 – drug, propellant, and aerosol or 
powder – but also the distribution of the deposition within the 
lung in relationship to the areas most affected by disease. The 
particles in different inhalers vary from 1 to 5 µm, so called 
“respirable” particles are ,6 µm. There are specific areas 
where the different sizes will deposit; at 2 µm they will be 
deposited in both the small and large airways, whereas larger 
particles will largely be deposited centrally and will not reach 
the peripheral airways. In asthmatics, there is increased smooth 
muscle volume and inflammation, which will be largely in the 
small airways, which is where we need to get to the receptors, 
either the B2 receptors for bronchodilator treatment or the 
steroid receptors for anti-inflammatory activity, and these can 
be reached only by small particles or via the bloodstream.5 
The difference between beclomethasone diproprionate (BDP) 
in a chlorofluorocarbon (CFC) or hydrofluoroalkane (HFA) 
inhaler demonstrates the difference in deposition,6,7 as do the 
Gamma recordings of aerosols of different diameter salbutamol 
  particles.8 In another study, patients inhaled fluticasone before 
lung resection surgery. The fluticasone concentrations were 
high in the central airway tissue, while concentrations in the 
peripheral lung tissue were low.8 The particle size affects not 
only the distribution, but also the total dose deposited in the 
lungs rather than in the oropharynx; measurements taken with 
different inhalers demonstrate these significant differences,9 
as does a comparison of BDP-CFC-free (Qvar®, Teva Phar-
maceutical Industries Limited, Petach Tikva, Israel), an HFA 
formulation of BDP, and a CFC-BDP inhaler.10–12Journal of Asthma and Allergy 2011:4 submit your manuscript | www.dovepress.com
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A further factor that can affect the dose and distribution of 
drug deposition is speed of inhalation; fast inhalation results 
in greater impaction of particles in the oropharynx, but this is 
also particle-size dependent, as smaller particles can follow 
the airflow more easily. Formulations with a greater number 
of smaller particles are therefore less affected by the   variation 
in patient inhalation speed on the total lung deposition,   having 
negligible oropharyngeal deposition.13
To determine whether small airway inflammation should 
be specifically targeted for treatment in asthma therapy, two 
groups of patients were compared; one group with severe 
asthma but who did not suffer frequent exacerbations, and 
a group with difficult-to-control asthma who had frequent 
exacerbations.14 The differences detected were primarily in 
small airways inflammation, with significantly higher levels 
of inflammation in distal areas of the lung in patients who 
had frequent exacerbations, which was confirmed in another 
study showing significantly more evidence of distal inflam-
mation in patients with refractory asthma.15
In conclusion, it is important to consider the involve-
ment and importance of small airways in asthma and COPD, 
  selecting inhaled treatments that have the ability to reach all 
the airways, including the distal airways.
Small patients – small airways? 
Monitoring asthma in children
Professor Wim Van Aalderen, Vice 
Chairman, Emma Childrens’ Hospital 
AMC Amsterdam, The netherlands
The objectives of this presentation were to outline the history 
and guidelines of treatment of asthma in children, to review 
the treatments available, and to highlight some factors that 
should be considered in making treatment effective and 
appropriate in young patients.
In the 1950s it was shown that corticosteroids were effec-
tive in the treatment of asthma; in the 1970s the first inhaled 
corticosteroids (ICS) – betamethasone and budesonide – 
came to the market. Formulations were improved over the 
next 20 years, with the small-particle ICS introduced in the 
1990s. The earliest study of budesonide vs salbutamol was 
made with the aim of discovering whether interfering with 
the autonomic nervous system was better than treating the 
inflammation, which was known by this time to affect the 
airway wall.16 The ICS proved far better than treatment with 
a short-acting β-agonist, demonstrating that bronchial hyper-
responsiveness decreased over the months of treatment in 
moderate to severely asthmatic children. Symptoms were 
reduced within 2 weeks, FEV1 improved within 2 to 4 weeks 
and then reached a plateau, and hyper-responsiveness con-
tinued to improve. Perhaps most importantly, exacerbations 
were reduced. This was confirmed in many studies, and is 
why these treatments are now cornerstones of asthma therapy. 
The studies continued with a comparison of children who 
continued to take the treatment and children from whom the 
treatment was withdrawn, and a return to baseline values in 
the untreated children demonstrated that control of asthma 
with ICS treatment should continue for a long time.
GINA (the Global Initiative for Asthma Management and 
Prevention in Children)17 defines the goal of asthma care as 
“to achieve and maintain control of the clinical manifesta-
tions of the disease for prolonged periods. When asthma is 
controlled, patients can prevent most attacks, avoid trouble-
some symptoms day and night, and keep physically active.” 
The latest management guidelines in GINA incorporate 
inhaled corticosteroids as a core component in steps 2 to 4 
of the 5-step recommendations for achieving asthma control 
in children and adolescents .5 years of age, and recommend 
that treatment should be stepped up until control is achieved 
and then maintained at that level.
Diagnosis and treatment of children under 5 years of 
age is a more difficult question; studies have shown that 
the younger the child, the greater the likelihood that an 
alternative diagnosis may explain recurrent wheeze, and 
that most children who wheeze will not continue to do so 
later in life. The management guidelines in GINA for this 
age-group have 3 steps, beginning with a β-agonist, adding 
in low-dose ICS or a leukotriene modifier as the second 
step, and in the third step both double-low-dose ICS and 
the leukotriene modifier. However, 2 years ago, studies by 
the European Respiratory Society Task Force added another 
dimension to the issue.18 These studies showed the existence 
of 2 asthma phenotypes in young children. One is episodic 
(viral) wheeze –   wheezing during discrete time periods, often 
in association with clinical evidence of a viral cold, with 
absence of wheeze between episodes. The other, much more 
resembling classical asthma in older children and adults, 
is multiple-trigger wheeze – wheezing that shows discrete 
exacerbations, but also symptoms between episodes. From 
the literature, it is known that the effectiveness of treatment 
with ICS is inconclusive in the episodic wheeze group, but 
in the second group treatment appears to be more effective, 
especially in the more allergic phenotype, though less effec-
tive than in older children with allergic asthma.
Are small particles better for small children? First there 
is the scientific evidence. A modeling study from Rotterdam Journal of Asthma and Allergy 2011:4 submit your manuscript | www.dovepress.com
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simulating a child’s in vitro inhalation through a metered dose 
inhaler (pMDI) and spacer which measured the lung dose 
during tidal breathing of a large-particle formulation of BDP 
and of a small-particle HFA-BDP. Lung deposition was sig-
nificantly higher with the small-particle HFA-BDP and rose 
with increases in tidal volume, in contrast to the CFC-BDP, 
which fell.19 Further in vivo studies in young children have 
demonstrated greater deposition with small particles than 
large, independently of tidal volume, and that deposition with 
large particles resulted in higher deposition with increasing 
age.20–26 The studies used a number of methods, including 
radiolabeling and urinary excretion measurements.
Secondly there is the clinical evidence.   Characteristically, 
children with severe or difficult-to-control asthma and 
  frequent exacerbations will have “normal” lung function, 
ie, as measured with FEV1, which is largely an indicator of 
large airway involvement. Hyperinflation is common, and 
it appears that distal airway impairment is more pronounced 
than proximal airway impairment. A US study in 50 centers 
of children 5 to 12 years of age with stable, moderate, symp-
tomatic asthma control receiving short-acting β2-agonists 
on an as-needed basis were treated with HFA-BDP (Qvar®) 
at lower doses (80 µg) than normally used with CFC-BDP 
(160 µg) were entered into a randomized, double-blind, 
placebo-controlled 12-week study.27 The children had FEV1 
between 50% and 80% of predicted and bronchodilator 
reversibility of .12%. The primary outcome was the mean 
change in FEV1 (% predicted) from baseline at 12 weeks 
compared with placebo, and the result was that low-dose 
HFA-BDP achieved significantly greater increase in FEV1 
(9.2%) than placebo (3.9%) (P # 0.01). Plasma cortisol levels 
at 12 weeks were increased for all groups (HFA-BDP 80 µg, 
HFA-BDP 160 µg, and placebo) but that the two HFA-BDP 
groups had levels below the reference range after 12 weeks 
compared with placebo, indicating the high safety level of 
the therapy. In a comparison of HFA-BDP with fluticasone, 
a 3-stage trial of control with 50% dose reductions at each 
stage for good control, continued dosage for intermediate 
control, and discontinuation for poor control demonstrated 
equivalent or better results for HFA-BDP compared with 
fluticasone.28 A trial comparing HFA-BDP with CFC-BDP 
and budesonide in a 1:2 dose ratio in school children dem-
onstrated equivalent efficacy for HFA-BDP at half dosage 
of the conventional inhaled steroid therapy.29 There are no 
clinical studies in pre-school age children.
The anatomical and physiological differences between 
children and adults are important; the pharynx and supra-
glottic area are less rigid in children, the epiglottis narrower, 
floppier, and closer to the palate and the larynx higher and 
closer to the base of the tongue. Absolute airway diameter 
is smaller in young children, with the result that airway 
resistance increases (Hagen–Poiseuille’s law states × 16 for 
a 50% reduction in radius), and the airways are more prone 
to obstruction and harder to reach. In addition, infants breathe 
through the nose, making delivery of inhaled drugs difficult, 
and young children have a higher respiratory rate, reducing 
the residence time of inhaled particles in the airways. When 
the particle size for inhaled drugs was chosen, it was based 
on a size for adults of 2 to 5 µm; in children, with smaller 
airways, this should be 0.75 to 1.2 µm.30
Are small particles better for children?
Small particles are less likely to impact in the upper respira-
tory tract, they have a longer residence time in the airways, 
with deposition through sedimentation, they are deposited 
more uniformly, and, quantitatively, produce better deposi-
tion as demonstrated both in vitro and in vivo. A commonly 
held view of pediatricians was that if a child starts crying 
the deposition will be better; 5 studies have demonstrated 
that the opposite is, in fact, true; crying deposition is low 
or negligible. If a face mask is being used and the child is 
turning their head, there is no deposition at all.
Side effects
A number of studies have compared HFA-BDP ultrafine 
particle therapy (Qvar®) with fluticasone, CFC-BDP, and 
budesonide in children to establish the potential for side-
effects such as growth retardation and HPA-axis effects; in 
all cases no significantly greater potential risks were found 
at normal therapeutic doses.28,31,32
Summary
Summarizing the critical requirements for inhaled asthma 
treatment:
•	 predictable and reproducible dose delivery,
•	 effective lung deposition,
•	 maximal clinical effect, minimal side effects,
•	 simple devices with minimal demands (co-ordination and 
co-operation).
The three questions that need to be answered are: is active 
inhalation possible, is there sufficient inspiratory flow, and is 
there good hand/lung co-ordination? If there is no active flow, as 
in very young children, we can give a pMDI plus a spacer or a 
nebulizer; if there is active inhalation but insufficient inspiratory 
flow we can give the same or a breath-actuated aerosol; if there 
is sufficient inspiratory flow we can also give a   dry-powder Journal of Asthma and Allergy 2011:4 submit your manuscript | www.dovepress.com
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inhaler (DPI); in pediatrics, hand–lung co-ordination is rarely 
good enough to give a pMDI without a spacer.
Conclusion
In conclusion, ICS treatment is effective with school children in 
asthma. It is effective in children with multiple-trigger wheeze. 
BDP CFC-free (Qvar®) in children  (Qvar® is licensed for use in 
many European countries for adults and children aged 5 to 12 
years of age but in other countries such as the UK, it is licensed 
only for use in adults including the elderly). is as effective as flu-
ticasone in a one-to-one ratio, and as effective as budesonide in a 
one-to-two ratio. Most studies indicate that BDP CFC-free 
deposition is better in pre-school children, although unfortu-
nately there are no studies of clinical effectiveness in preschool 
children.
Inhaled corticosteroid effect  
on severe asthma and COPD
Professor richard J Martin, MD, 
Chairman, Department of Medicine, 
Edelstein Chair in Pulmonary Medicine, 
national Jewish Health
In asthma, refractory asthma patients are the most   challenging 
regarding response to ICS. There are many reasons why 
patients do not respond well to ICS; in this symposium we 
are focusing on the issue of the small or distal airways.
The first question to ask is whether there is supporting 
anatomic evidence that the distal airways are involved in 
asthma and to a different extent than the central airways?
The question of “remodeling” of the airways is an important 
issue as the resulting airway changes can cause an   inability to 
achieve normal lung function. A post-mortem study compared 
the outer wall area of a control   population, of asthmatics who 
died from causes other than their asthma, and of patients who 
died from asthma.33 In the medium-size airways, 2 to 4 mm, 
there was no statistically significant   difference between groups. 
In the more peripheral lung, ,2 mm, both asthma groups had 
significantly increased outer wall area compared with the con-
trol population, but there was no difference between the two 
asthma groups. This suggests that, regardless of the severity 
of asthma, remodeling changes occur in the distal lung.
Another post-mortem evaluation used a bronchogram 
technique to visualize the airways of 3 subjects, 1 who suffered 
fatal asthma, 1 whose asthma had been “well controlled,” and 
1 normal, nonasthmatic control. The fatal asthma case clearly 
had blockages of the major airways that would have prevented 
gas exchange. The “well-controlled” asthma patient, who 
died from other causes than asthma, had fine branching of the 
airways but little evidence of penetration in the alveoli by the 
marker dye used. The normal individual had fine branching 
of the airways with clearly visible dye reaching the alveolar 
space. This demonstrated that even in “well-controlled” 
asthma, anatomic abnormalities occur in the distal airways.
Is there supporting physiological and clinical evidence 
that the central and distal airways differ in asthma?
A physiological evaluation of peripheral airway 
resistance showed that even in mild asthmatics this was 
markedly elevated compared with normal controls.34 After 
  bronchodilator therapy, this was still significantly elevated. 
Thus, physiological differences of distal lung dysfunction 
are apparent even in mild asthma.
A physiological study of asthmatic children demonstrated 
differences in the distal airways between children with stable 
asthma and children who had exacerbations.34 No significant 
differences in FEV1, total lung capacity, functional residual 
capacity, or residual volume were found, but there was signif-
icantly elevated closing volume in the unstable asthma group. 
If a child with an elevated closing volume is to encounter an 
asthmatic trigger such as an upper respiratory infection or 
allergen, this could result in closure of the distal airways due 
to this instability, and consequently an exacerbation.
Since a major characteristic of asthma is airway inflam-
mation, is there physiological evidence to support a differ-
entiation between central and distal inflammation?
Tests during the early morning hours have been carried 
out to detect differences in the circadian rhythm airway 
reactivity. Even asthma patients who do not have excessive 
overnight falls in lung function still have approximately two-
fold increases in bronchial hyper-responsiveness. In asthma 
patients who have large night-time falls in lung function, 
bronchial hyper-responsiveness can increase by 8 times.
By measuring the relationship between lung volume 
and airways resistance asleep and awake, changes in the 
distal lung function of asthma patients can be detected.35 
Increasing lung volume will normally result in decreasing 
resistance, a relationship that continues to hold in waking 
asthma patients whether upright or reclined. During sleep, 
however, the relationship starts to break down, with resis-
tance maintained despite increase in lung volume. This 
suggests that distal inflammation and edema are responsible 
for this physiological uncoupling of the lung parenchyma 
and airways in asthma. This “nocturnal uncoupling?” 
of volume and resistance was supported by a difference 
in proximal and distal inflammation in a bronchoscopy 
study carried out in an asthma control population who did Journal of Asthma and Allergy 2011:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
66
Dalglish and Priestley
not have worsening asthma at night and another that did. 
  Biopsies were performed at 16:00 and 04:00 hours in the 
fifth generation airway and the alveolar tissue area.36 During 
the afternoon study, there were no statistically significant 
differences between groups or locations in the inflamma-
tory response. At 04:00 hours the volume of eosinophils in 
the alveolar tissue area was tremendously increased in the 
nocturnal asthma group. These studies demonstrated that 
uncoupling of the airways and lung parenchyma occurs at 
night, resulting from the inflammatory response being the 
greatest in the distal airways.
Does particle size of inhaled medication alter lung 
physiology and inflammation? There is a wide variation in 
particle size between the available ICS medications, rang-
ing from 1 µm to .4 µm, and between aerosols in solution 
and in suspension. Lung deposition studies demonstrate a 
clear trend for greater deposition with smaller particle size, 
with the ultra-fine particle in HFA-BDP (Qvar®) resulting 
in deposition rates in excess of 50% of the dose, while the 
3.5 µm particles of BDP-CFC can result in deposition rate 
as low as 4%.6,7 Air-trapping, measured as lung attenua-
tion, has been clearly demonstrated to be significantly less 
changed after treatment with CFC-BDP than with HFA-BDP 
treatment.37
In conclusion, there is supporting physiologic and clinical 
evidence that the central and distal airways are different in 
asthma, that there is a differentiation between central and dis-
tal inflammation, that the particle size of inhaled medication 
alters deposition, and that particle size of inhaled medication 
alter lung physiology and inflammation.
Does particle size of inhaled medication alter asthma 
outcome? The short-term studies of 4 to 12 weeks suggest 
that the answer is yes, but longer-term studies are needed to 
confirm these observations.
The question of the use of ICS in COPD is more difficult 
than for asthma; there are arguments both for and against.38 
They are licensed for use in COPD in Germany, Austria, 
Switzerland, and the US. It should be noted that ICS are not 
licensed for COPD in France, and the UK only in combina-
tion with a long-acting beta agonist.
The first part of the problem is that the COPD phenotypes 
are not well understood, and that the disease has a complex 
pattern of airway vs parenchymal vs mixed vs inflammation 
dimensions. There is emphysema-predominant COPD, with 
centrilobular emphysema, panlobular emphysema, paraseptal 
emphysema, and bulla. There is also airway-predominant 
COPD, with large and small airway disease, air trapping 
bronchial wall thickening, bronchial dilatation, mucus, 
and airway collapse.39 In some of these pathologies steroid 
treatment does not have a logical therapeutic role and may 
indeed be potentially harmful.
As studies of ICS therapy for managing COPD have 
yielded conflicting results for survival and risk of adverse 
events, a systematic review and meta-analysis of the available 
randomized, controlled trials was published in 2008.40 Eleven 
studies, including 14,426 subjects, were selected, all of more 
than six months duration, to form a comparison of ICS with 
nonsteroid inhaled medication for COPD. One-year all-cause 
mortality was not found to be significantly different between 
the two treatment groups, but the risk of pneumonia was 
significantly higher in the ICS group. Subsets of patients for 
whom the pneumonia risk was found to be greater were:
•	 ICS dose .100 µg (BDP equivalents),
•	 Shorter duration of ICS use ,2 years,
•	 FEV1 ,40% predicted,
•	 Combined ICS and bronchodilator therapy.
Further investigation is needed to determine which COPD 
patents would benefit from the use of chronic ICS.
Economic issues in asthma and 
COPD: disease burden, treatment 
and management
Andrew Briggs, Public Health and Health 
Policy, University of Glasgow
Health economics is concerned with broad issues of the rela-
tionship between cost and benefit over the whole spectrum 
of illness and healthcare, both direct and indirect. Examining 
such issues in a wider sense than purely medical extends to 
all aspects of the impact of illness and treatment in general 
economic terms.
In this way it is possible to compare respiratory disease 
treatment, for example, with treatment of cardiac conditions. 
As health economists we are concerned also with the benefits 
of treatment not only in terms of survival but in more subjec-
tive and difficult to measure areas such as quality of life.
Three topics were discussed in this presentation: the bur-
den of disease in COPD, which was the subject of a recently 
conducted analysis; two specific Health Economic evalua-
tions, TORCH in COPD and GOAL in asthma (see below); 
and a particular example of economic analysis of the impact 
of inhaler devices and technique in asthma management.
COPD: the economic burden of the disease
The direct financial cost to the health service of COPD in 
the UK is estimated at £486 to £850 million, alternatively Journal of Asthma and Allergy 2011:4 submit your manuscript | www.dovepress.com
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viewed as £780 to £1,150 per patient per year.41 The indirect 
costs, ie, of lost productivity within the labor market, could 
double this, since 44% of COPD patients are below retirement 
age and 24% of these are prevented from working through 
COPD. For patients not of working age, 5% of the patients’ 
carers missed work to provide care.42
In Scotland, unusually detailed information is available for 
a prospective cohort of 15,402 men and women recruited over 
the 4 years from 1972 to 1976, giving baseline data includ-
ing spirometry for each participant and more than 30 years 
follow-up on mortality and. FEV1, while having limits in its 
value in clinical medicine, is linked to survival, and this was 
seen in the correlation of FEV1 with survival in the   midspan. 
There was clear separation between the groups in this cohort, 
even after correction for age and other factors.43
There have been changes in the mix of treatments in 
COPD over time, with significant increase in awareness of 
COPD over last 10 years. Changes to both the management 
and treatment of COPD have occurred, with the issue of 
guidelines: British Thoracic Society (BTS)/Scottish Intercol-
legiate Guidelines Network (SIGN) first in 1997, followed 
by GOLD (2001, updated 2006) and NICE (2004). New 
drug treatments, both through licensing of new products and 
particularly combination products, are probably responsible 
for the most important changes in treatment patterns. Changes 
in management have included the General Medical Services 
Contract, with rewards to clinical practices for diagnosis of 
COPD, diagnosis confirmed by spirometry and ongoing man-
agement. These changes in therapy and management have 
had a large impact on the cost; a discussion with respiratory 
physicians has revealed that the “basket of products” used 
routinely in the management of COPD today is approximately 
7 times the cost of the products used 5 years ago.
So much for the disease burden; as health economists 
we are not concerned quite as much with the burden itself as 
on what effect management of the disease has in changing 
that burden. Two examples of this economic evaluation of 
management follow:
Example 1: GOAL (the Gaining Optimal Asthma 
control)44,45 study (asthma)
This study was set up to test prospectively whether sustained 
asthma control assessed using a composite measure derived 
from GINA/NIH (National Institutes for Health) guide-
lines is achievable. The idea was to aim for total control 
of asthma and to study how far particular pharmaceutical 
products advanced outcomes towards that target. The main 
comparison was between fluticasone propionate alone versus 
fluticasone propionate in combination with salmeterol. The 
original clinical trial results were published in 2004 and the 
economic analysis 2 years later.
The results show that the combination therapy produced 
a higher proportion of patients spending time in the higher 
control states, but that treatment costs were higher, with only 
a very small benefit from lower health care costs, but that 
there was a significant gain in quality of life.
The value message that comes out is very positive, 
considered in the light of NICE evaluations looking for 
£20,000 to £30,000 per quality-adjusted life year (QUALY) 
– the combination treatment achieving £5,000 to £8,000 per 
QUALY benefit over the fluticasone propionate treatment 
alone. The study demonstrated the value of the combina-
tion product through the benefit obtained, not through cost 
offsets achieved.
Example 2: The TOrCH46,47 study (COPD)
TORCH (TOward a Revolution in COPD Health) was a 
3-year, international, multicenter, placebo-controlled, double-
blind, randomized, parallel group trial. The first patient was 
recruited in 2000, with results becoming available in 2006. 
The TORCH study recruited patients from 444 centers in 
a total of 42 countries worldwide, including the Americas, 
Europe, Australasia, Asia, and Africa.
Patients  with  moderate-to-severe  COPD  were 
recruited. The inclusion criteria for patients in TORCH 
were: age 40 to 80 years, an established clinical history 
of COPD, a smoking history of #10 pack-years, baseline 
FEV1 , 60% predicted (prebronchodilator), ,10% reversibil-
ity in predicted FEV1 and a FEV1/forced vital capacity (FVC) 
ratio #70%.
The study design included a 2-week run-in period, 
a 3-year treatment phase, and a 2-week follow-up phase. 
Patients were randomized to 1 of the following 4 treatment 
groups, all administered twice daily via the Diskus® DPI 
device (GlaxoSmithKline, UK): placebo, salmeterol 50 µg, 
a long-acting beta-2 agonist, fluticasone propionate 500 µg, 
an ICS, and salmeterol/fluticasone propionate 50/500 µg.
The pooled results, cost by region, and QUALYs by region 
are shown in Table 1. Notably, all costs are very much greater 
in the US than in all other regions, but this must be balanced 
by awareness of willingness to pay much higher health costs; 
in the graphical view of the final results (Figure 1), the very 
much higher figures for the US need to be related to a usual 
acceptable figure of $100,000 per QUALY in that region. This 
absolute cost difference discounted, the ratio of comparative 
cost per QUALY, represented by the steepness of the line is Journal of Asthma and Allergy 2011:4 submit your manuscript | www.dovepress.com
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similar across the regions and demonstrated the superiority 
of the combination product over the components.
Management and delivery
Health economic evaluations in these and other studies of 
managing delivery of respiratory treatment are providing 
emerging evidence that devices are important, largely obser-
vational at present, but important for hypothesis generation, 
which perhaps should lead to this topic making a step up the 
evidence hierarchy, as other commentators at this meeting 
have also suggested. Inhaler technique is similarly important, 
often being confounded with the effects of the medication 
being delivered, which is a challenging area for analysis; as 
in a similar way there is a relationship with getting the drugs 
into the right place in the lungs, the importance of which is 
evident from earlier presentations at this meeting.
There is a clear potential for devices and delivery tech-
niques to be demonstrably cost-effective, allowing better 
use of existing therapies, particularly in the light of the 
ever-increasing cost of combination therapies. Evidence is 
required that would then justify investment in improvements 
of technique and delivery vehicle. Analyses such as GOAL 
illustrate the potential framework for providing evidence 
of their value by evaluating the way that treatment acts on 
control, as improved control improves health-related quality 
of life and reduces costs, creating a real value message.
Summary
Respiratory disease creates a clear burden to society in 
health care costs, days off work, morbidity, and mortality. 
Cost effectiveness analysis is required to show value of new 
treatment interventions; public health services cannot afford 
to provide all new treatments that are presented to them, 
particularly in this time of fiscal restraint and national debt 
issues. Devices and improved inhaler technique offer the 
potential for better use of existing effective therapies, and 
should be evaluated head-to-head in randomized clinical 
trials with new drug therapies.
Table 1 TOrCH:47 pooled costs per region and QUALYs per region
Pooled results, EQ-5D countries Cost by region, EQ-5D countries*
Cost ($US)* QALYs
Mean SE Mean SE PL SAL FP SFC
PL 9,467 584 1.941 0.020 US 18,241 21,787 21,188 25,196
SAL 10,995 552 1.949 0.019 E Eur 4,403 6,141 6,883 7,196
FP 11,520 619 1.965 0.019 W Eur 5,856 6,209 6,886 7,290
SFC 12,950 586 2.022 0.018 Other 3,993 5,423 5,423 7,006
Notes: *Local Currencies translated into $US by use of purchasing power parity statistics; adapted from Briggs et al.47
Abbreviations: PL, placebo; SAL, salmeterol; FP, fluticasone proprionate; SFC, salmeterol plus fluticasone proprionate.
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Figure 1 TOrCH:47 cost effectiveness per QUALY gained.
Note: reproduced with permission from the European respiratory Society ©.
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Challenges in clinical practice
Professor David Price, Professor of Primary Care 
respiratory Medicine, University of Aberdeen; Honorary 
Professor University of Adelaide, international Primary 
Care research Group (iPCrG) research sub-committee 
chair; Member of Allergic rhinitis and its impact 
on Asthma (AriA) executive, sessional respiratory 
physician for children and adults, norfolk, UK
This presentation sets out to challenge views about evidence-
based medicine.
A typical grading of clinical evidence is shown in Table 2. 
The highest grading is therefore the RCT. Are such trials 
measuring effectiveness … or efficacy? To define these 
terms, effectiveness would be the outcome for a real-world 
asthma patient – it would be what you would aim to achieve 
in day-to-day clinical practice. Efficacy would be the effect 
of a particular treatment on a patient in a clinical trial. The 
question is whether the efficacy achieved in that trial would 
be reflected in the   effectiveness of treatment in everyday 
clinical practice.
 To examine this question, in an asthma trial what patients 
can be selected for such a trial? As we know, a patient must 
have a clinical diagnosis of asthma, 15% reversibility, have 
adequate inhaler skills, have symptoms, have lung function 
between 50% and 80% of predicted, not smoke, not have 
significant rhinitis, not have reflux, not have heart disease, 
not have co-existing COPD, must be willing to take   treatment 
regularly, to write a diary twice a day, and to come to the doc-
tor once a month. The result of that trial will be a measure of 
efficacy. However, such a patient population is not reflective 
of real life – even the willingness to take part in a clinical 
trial would rule out many people. So this measure of efficacy 
needs to be tempered by results from a real-life population to 
understand effectiveness.
A real-life population would introduce the effect of 
compliance and adherence, which can be deliberate or 
nondeliberate, and be influenced by length of the treatment 
period, by inhaler technique, attitude to treatment, patient 
education and motivation, cost of treatment and many other 
factors. For example, in a double-blind trial in Sweden of 
inhaled steroids in children, though compliance normally 
decreases with time, 50% of the patients in the active arm 
were compliant at the end of the trial, after 2 years, a remark-
able figure.48 Patients are smart enough to recognize when 
they are on the active treatment, and will keep on taking it. 
To get a real picture of effectiveness, we need to study for 
long enough to allow factors such as real-life compliance 
to become clear. So when we consider clinical trials, we 
should consider:
•	 The design of the study,
•	 The types of patients involved,
•	 The types of outcomes,
•	 How we should describe the data seen.
Professor Sir Michael Rawlins, the Chairman of the UK 
National Institute for Health and Clinical Excellence since 
1999 (ex-Chairman of the Committee on Safety of Drugs), 
an eminent physician, recently said this to the UK Royal 
College of Physicians:
“Randomized controlled trials (RCTs), long regarded 
at the ‘gold standard’ of evidence, have been put on an 
undeserved pedestal. They should be replaced by a diver-
sity of approaches that involve analyzing the totality of the 
evidence-base.”
This statement challenges many people’s thinking, which 
is something we need to do. To take an example, the authors 
of a trial published in the British Medical Journal49 made 
this statement:
“Parachutes reduce the risk of injury after gravitational 
challenge, but their effectiveness has not been proved with 
randomized controlled trials.”
Which is a statement about a situation where a random-
ized clinical trial is clearly not possible. Clinical trials should 
not be a hierarchy, they should be regarded as complementary 
forms of evidence, be compared with each other, the evidence 
considered as a whole to consider what it means.
Table 2 Typical grading of clinical evidence
Grade of  
recommendation
Level of  
evidence
A 1a Systematic review of rCTs
1b individual rCT (with narrow  
confidence interval)
1c All or none – patients die  
without or live with
2a Systematic review of  
cohort studies
2b individual cohort study  
(including low-quality rCT;  
eg, ,80% follow-up)
2c Outcomes research
C 3a Systematic review of  
case-control studies
3b individual case-control study
4 Case-series (and poor quality  
cohort and case-control studies)
D 5 Expert opinion without explicit  
critical appraisal, or based on  
physiology, bench research or  
first principlesJournal of Asthma and Allergy 2011:4 submit your manuscript | www.dovepress.com
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To understand effectiveness we need 4 strands of 
evidence:
1. Theoretical evidence
This gives us give us a good model of why something might 
work; for example, knowing that inhaled steroids reduce 
inflammation in asthma.
2. Classical double-blind, double-dummy rCTs
These are the gold standard to prove efficacy; but we need 
to recognize that they do not represent real life, and tell us 
very little about effectiveness.
3. Pragmatic trials
Still randomized, but more like real life, with few patient 
exclusions (such as smokers, concomitant rhinitis, poor 
compliance), less frequent attendance, long study times. Still 
requiring consent and still rigorous, they still do not represent 
real life, but they help us to understand more, and are very 
useful for health economic analysis.
4. Observational data
These are gained from large databases such as the UK Gen-
eral Practice database (GPRD), which contains 3.5 million 
patients, with all their prescribing data, consultations, and 
hospitalizations. These are real-life patients; the weakness 
is that they are not randomized, although there are ways of 
handling this, such as matching patients.
These 4 different strands can each give different 
information.
Other important design issues
One of the weaknesses in many of our asthma and COPD trials 
is that they are not true “intention-to-treat analysis,” because 
usually patients who stop treatment also drop out of the study 
– although the way people drop out of treatment is not random. 
True intention to treat keeps patients enrolled who are willing 
to continue supplying study data, thus giving opportunity to 
investigate reasons for dropping out or changing treatment, 
and to track eventual outcomes. Long duration of at least 
a year, real-life patients, and studies that mimic “real-life” 
clinical practice would also help in increasing the usefulness 
of trials. Only 2 examples of intention-to-treat clinical data 
from clinical studies in respiratory medicine were found: the 
TORCH50 and UPLIFT (Understanding Potential Long-term 
Impacts on Function with Tiotropium)51 trials had an approach 
to mortality data different from other outcomes in these trials 
and in most other respiratory studies, giving long-term total 
mortality of all patients entering the trial rather than the stan-
dard approach where patients who stopped treatment would 
have been taken out of the studies. The results from TORCH 
show a “true” risk reduction of 17.5% rather than the 24% 
that would have been obtained from the standard approach, 
in UPLIFT 13% vs the 16% of the on-treatment approach. 
One could argue these are more realistic results.
What types of patients?
To quote Sir Michael Rawlins again:
“RCTs are often carried out on specific types of patients 
for a relatively short period of time, whereas in clinical prac-
tice the treatment will be used on a much greater variety of 
patients – often suffering from other medical conditions – and 
for much longer. There is a presumption that … the benefits 
shown in an RCT can be extrapolated to a wide population; 
but there is abundant evidence to show that the … value of 
an intervention is often missed in RCTs.”
To take an example, if the first studies of ICS had been 
carried out in children with viral wheezing, or in smokers, we 
might have concluded that ICS do not work. Classical asthma 
RCTs have exclusions that reduce the eligibility of a normal, 
representative patient population by over 90%; an example is 
a Norwegian asthma trial in which the exclusions resulted in 
only 1.2% of the patient population being eligible.52
Does it matter?
Would using a wider range of patients make the results dif-
ferent? Surely, to categorize results from 1.2% of the patient 
population as “grade A” evidence is not sensible? We know 
that many things have a direct impact on asthma control, but 
are often excluded. We also know that inhaler technique has 
an impact on asthma control from a study that showed that 
poor ability to use inhalers was related directly to asthma 
control.53 Other exclusions, such as rhinitis, smoking, and 
adherence, all affect asthma control. A cross-sectional study54 
showed this, rhinitis patients being 4 times more likely to 
have poor asthma control.
We know that smoking reduces the effect of ICS for 
3 reasons: smoking changes inflammation to a more neu-
trophilic pattern,55 it interferes with the mechanism of ICS 
through oxidative stress,56 and it leads to the excess produc-
tion of leukotrienes,57 which we know are steroid-resistant. 
A GPRD database study of our own of the effect on smok-
ing on asthma control showed that the chance of gaining 
control was 50% less for smokers with the use of increased 
ICS, 30% less likely using long-acting beta-2 agonists, and 
maintained benefit using leukotriene antagonists. Clearly, we Journal of Asthma and Allergy 2011:4 submit your manuscript | www.dovepress.com
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need to include smokers in clinical trials so that we know 
how drugs work with them. So, I agree strongly with Sir 
Michael Rawlins – we need a breadth of asthma evidence, 
which would include a whole range of patients with a range 
of co-morbidities and severities, not just those with 15% 
reversibility, FEV1 between 50% and 80%, and so on.
What types of outcome?
Does it matter? Is FEV1 a perfect measure? We heard in this 
meeting how poorly it correlates with symptoms. Is control 
enough? In a randomized, controlled trial comparing BTS/
SIGN-guideline-based treatment with sputum-eosinophil 
based treatment, the outcome, measured in patient-reported 
symptoms and quality of life, showed equal efficacy.58 
Exacerbations, a too-often forgotten aspect of asthma, were 
3 times as common in the guideline-based treatment as in 
the sputum group. In another long-term trial with a success 
definition based on proxies of GINA control including short-
acting beta agonist and oral steroid use, long-acting beta-2 
agonist treatment gave a higher chance of achieving control 
than using increased inhaled steroids.59 When analyzed for 
exacerbations, steroid use was much more effective. So, as 
with patients, we need a broad range of outcome measures 
in asthma to help us determine real effectiveness.
How should we see the data?
Mean data, as a basis for making decisions, can be very mis-
leading. Information on the range of responses can reveal quite 
different information and yet is often not presented meaning 
the potential for a different insight is lost. A trial in children 
that showed that half the children did equally well on leukot-
riene antagonists and ICS, but the cross-over data showed 
that 1 in 3 children did better on inhaled steroid and 1 in 6 
did better on leukotriene antagonists.60 This would suggest 
that guideline-based recommendations to step up treatment 
may be missing the point that changing the treatment may 
bring a better result. As another example, the Greening trial 
of long-acting beta-2 agonists vs increased ICS showed that 
patients did about equally well on both treatments.61 Closer 
examination of the data, however, revealed that some patients 
did very well on the long-acting beta-2 agonist (LABA), and 
some did very well on the ICS.   Ideally, we should always see 
the distribution of data as well as the mean results to ensure 
that these variations in response are identified.
Guidelines
Looking at the British guidelines on the management of 
asthma, as an example, we see the statement that: “inhaled 
steroids are the most effective preventer drug for adults and 
older children for achieving overall treatment goals. In fact, 
the word effective here should be efficacious, as effective-
ness has never been tested. As a demonstration of the dif-
ference, a recent government-sponsored pragmatic trial, an 
economic assessment of the use of leukotriene antagonists in 
primary care at step 2 of the UK national asthma guidelines 
(Elevate62) was carried out over 2 years. This was performed 
in a relatively unrestricted population, including smokers and 
patients with relatively poor reversibility. While the end result 
in terms of lung function and quality of life showed almost 
exactly equally effectiveness, analysis of adherence showed 
that the leukotriene antagonists achieved 61.4% adherence 
to treatment vs 41.1% for ICS. This demonstrates the differ-
ence between efficacy and effectiveness in a more real-world 
setting. A comparison of the demographics and drop-out 
rate of Elevate,62 GOAL,44 and the IMPACT (Improving 
Asthma Control Trial) study63 showed a significant difference 
in how close the patient population in these trials was to a 
real-life distribution and how this can potentially impact on 
the applicability of these trials’ results to everyday clinical 
effectiveness.
Another statement from the UK asthma guidelines is as 
follows: “In adults, there is no clinical difference in effec-
tiveness of pMDI ± spacer v DPI. Breath-actuated MDI is 
as effective as pMDI. More recent DPIs are as effective as 
older DPIs.” Does anybody believe this? Why does it say 
this, when we all know that it’s not true? It is because of the 
evidence hierarchy; in the randomized controlled trials on 
which it is based, patients were excluded if they could not 
operate both a pMDI and a breath-actuated inhaler (BAI) 
effectively. Unsurprisingly, therefore, the trial concluded that 
they were both equally effective!
Compare that “finding” with a more “real-life,” observa-
tional study. Analyzing a general practice database of patients 
who either started on ICS for the first time, or who had an 
increase in their dose, a 1-year baseline period to define 
confounding factors/match populations was followed by a 
1-year outcome period.64 The results showed an increased 
chance of gaining control with a BAI or DPI vs a pMDI, in 
both first-use and increased-dosage groups. So the device 
does matter. The guidelines, had they been based on a range 
of evidence as opposed to the evidence hierarchy, would have 
come to much more sensible conclusions.
One more example: the guidelines state: “Many studies 
now show Qvar® equivalence at half the dose of CFC-BDP 
pMDI,65 whereas non-Qvar® HFA-BDP pMDI studies show 
equivalence at 1:1 dosing.” That is what the randomized trials Journal of Asthma and Allergy 2011:4 submit your manuscript | www.dovepress.com
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show – in classical asthma; but people with poor technique 
were excluded, as were patients with unstable asthma, with 
frequent exacerbations who, as we have heard, may have 
more small airways involvement. What about more real-life 
patients? There is a 1-year pragmatic trial of patients with 
stable asthma, where patients were given half the dose of 
Qvar® or the full dose of CFC-BDP,66 with a significant differ-
ence in quality of life and symptom-free days at 12 months.
I hope I have challenged your thinking about evidence-
based medicine; do you think that Sir Michael Rawlins 
was right, that we need a new approach to evidence? That 
we need to take the whole range of evidence into account, 
looking at study designs to make sure of external as well as 
internal validity, a variety of outcomes, a true intention to 
treat approach? If we do we will often get results that surprise 
us. We have to deal with the whole range of people with 
asthma and to do whatever we need to for them, however 
strange it might be.
Real-life device trials
Professor nicolas roche, Hôtel-Dieu, 
Paris
Three factors are major determinants of appropriate treat-
ment delivery with inhaler therapy, since they condition 
particle size (mass median aerodynamic diameter) and 
respiration mass/fraction: the device itself, such factors as 
internal resistance; the device contents, ie, pharmacological 
agent, excipients, propellants; and the inhalation technique. 
With MDIs, including BAIs, the content is actively pro-
pelled towards the airways; with DPIs the act of inhalation 
is the only propellant – inhalation has to be fast and furi-
ous. The ideal device would require no co-operation by the 
patient – such a device does not exist. Inhalation technique 
is usually well controlled in randomized trials but not in real 
life. Therefore, controlled studies are not sufficient to get 
an accurate picture of the results that will be obtained in the 
real-world patient’s life.
Why is it important to perform real-life studies on 
inhalation technique and devices?
What we would hope to achieve with ICS is that the majority 
of asthma patients would be well controlled, and a signifi-
cant proportion would be totally controlled. What is actu-
ally seen in large surveys of the general population is that 
about 5% of asthmatics are controlled.67 In a real-life study 
of general practice 28% were controlled, either acceptably 
(7%) or optimally (21%), while 72% were not acceptably 
controlled.68
The reasons for such suboptimal levels of control are 
shown in Table 3.
Accuracy of assessment and perception
The accuracy of assessments of control is an important issue; 
the same population in which control was found to be unac-
ceptable in 72%, when asked how their asthma was, actually 
reported that it was badly controlled in only 8%, moderately 
in 39%, well in 32%, and perfectly in 21%. So differences 
in perception play a major part in evaluations, an issue con-
firmed by comparisons across the world of patient-perceived 
control vs severity of symptoms. In another comparison of 
physician-reported symptom occurrence vs patient-reported 
symptom occurrence, very large discrepancies were shown 
between the two, with patients reporting almost 6 times the 
incidence of symptoms, such as speaking problems, com-
pared with the physicians.
These problems of assessment are true for inhalation tech-
nique as well as control, many physicians underestimating 
the proportion of device misuse by patients69 and overesti-
mating the education they give to patients about inhaler use. 
Studies found that inhalation technique was not appropriate 
in health professionals either: inappropriate technique was 
observed in 65% of nurses, 63% of general practitioners, 
53% of fellows, and 15% of specialists. Education in inhaler 
technique requires a cycle of explanation, demonstration, 
checking of the patient’s technique, and then repeating or, 
if necessary, changing the device type if correct performance 
is not achieved. Such education is very important; with some 
devices, patient education has been shown to reduce the rate 
of critical errors from almost 60% to around 10% of patients. 
Critical errors, defined as errors that could substantially 
affect the dose delivered to the lung, can be nonspecific to a 
particular device, such as failure to inhale through the mouth-
piece, or device-specific, such as blowing into a DPI before 
inhalation. In a study of 3811 patients using a variety of 
inhalers, 76% of patients made at least one error with pMDI 
compared with 49% to 55% with BAIs (Figures 2 and 3).70 
Table 3 Possible reasons for such suboptimal levels of control
Insufficiently rigorous assessment of control
inadequate maintenance therapy
rhinitis, GEr
Environmental exposures
Smoking
Being overweight
Device and inhalation technique problems
Poor compliance
Abbreviation: GER, gastroesophageal reflux.Journal of Asthma and Allergy 2011:4 submit your manuscript | www.dovepress.com
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What are the consequences of poor inhalation technique in 
real life? Inhalation technique is critical to the success of 
asthma therapy, poor technique with MDIs causing 60% 
lower lung deposition and 30% less bronchodilation, and 
thus poor asthma control. In a study in which patients were 
treated for the lung deposition achieved by 18 patients using 
a pMDI or a BAI, poor pMDI co-ordinators achieved lung 
deposition less than 7% of the dose, good pMDI coordinators 
25% of the dose and BAI users 23%.71 In another study of 
errors and omissions among 3955 unselected asthmatics on 
pMDI-delivered ICS were recorded72 (Table 4).
The consequences of the above errors and omissions 
showed clearly in the asthma control outcome of these 
patients, demonstrating also the fact that, even in good co-
ordinators, other errors can compromise long-term asthma 
control. Evaluation of medical visits by asthmatics demon-
strates a rise in emergency visits and increased beta agonist 
use with inhaler misuse, made worse still by poor co-ordina-
tion. Unsurprisingly, this is also confirmed by the effect of 
correcting inhaler use to increase the efficiency of inhalation 
flow by means of training devices, questioning, and   education 
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Table 4 Errors and omissions among unselected asthmatics on 
pMDi-delivered iCS70
Cause of misuse n %
Omissions
  no removal of cap 16 0
  inhaler not held correctly 260 7
    Device not actuated at the  
beginning of the inspiration
748 19
  No slow inspiratory flow 1348 34
  no complete inspiration 919 23
  .1 puff 739 19
    no 5-s breath holding period  
at the end of inspiration
1753 44
Errors
  Forced expiration 1077 27
  no expiration 440 11
  inspiration by nose 480 12
    Actuation at the end  
of inspiration
708 18
  no inspiration 224 6
Abbreviations: iCS, inhaled corticosteroids; pMDi, metered dose inhaler.
by a health professional. In a study in which 256 trained 
pharmacists asked 727 patients about control and compliance, 
checked inhaler technique, and gave education for a mean of 
6 minutes on 2 occasions, optimal technique increased from 
176 patients (25%) to 678 (80%).73 Significantly, 67% of 
patients reported that they had never previously used a device 
in front of a health professional. Importantly, improvement 
in inhalation technique was accompanied by better asthma 
control and adherence to treatment at 1 month.
Can the device influence control in real life?
An analysis of the Doctors’ Independent Network database 
(DIN-LINK) primary care database of treatment of asth-
matic children74 has demonstrated a relationship between 
the device type and indicators of poor control; children using 
a breath-actuated device required less beta-2 agonists, less 
oral steroids, less antibiotics, and made fewer visits to their 
general practitioner for asthma problems.
A series of very large-scale studies of the UK GPRD from 
1997 to 2006 are in progress to attempt to answer the question: 
“Does the device/formulation used to administer ICS change 
anything in asthma or COPD control?” The studies deal with:
•	 HFA extra-fine particle betamethasone dipropionate 
(BDP) (Qvar®) vs fluticasone in asthma (concerning the 
effect of formulation)
•	 HFA-BDP vs CFC-BDP in asthma
•	 Fixed-dose ICS/LABA combinations in pediatric 
asthma
•	 CFC-BDP vs fluticasone proprionate in COPDJournal of Asthma and Allergy 2011:4 submit your manuscript | www.dovepress.com
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For all these analyses, the study period for each patient 
includes the 12 months before (baseline) and after (outcome) 
an index event, which is a first prescription or first increase 
of ICS. The patient age range is 5 to 60 years, and careful 
matching and historical data standards are incorporated into the 
protocols. Primary outcomes are a composite proxy measure of 
control (no emergency visits or oral steroids) and exacerbations 
requiring hospital treatment or oral steroids. A secondary out-
come is treatment failure leading to exacerbation or treatment 
increase. When adjustments for baseline differences between 
the treatment arms are not sufficient, matching ensures that 
treatment groups are comparable. Matching variables include 
age, height, weight, sex; asthma consultations; and – for the 
ICS increase cohort only – prior ICS dose.
Initial results for the Qvar® vs fluticasone analysis, after 
matching for severity, are that:
•	 Doses of extra-fine HFA-BDP (Qvar®) are half that of 
fluticasone proprionate
•	 Patients in the extra-fine HFA-BDP (Qvar®) group
−	 Are more frequently controlled
−	 Have more treatment success
−	 Have less treatment increases
•	 Suggesting an increased efficacy when the ICS is deliv-
ered as extra-fine particles
Conclusion
Real-life studies demonstrate that
•	 Asthma control is suboptimal,
•	 Poor inhalation technique is frequent, and decreases 
asthma control
•	 Misuse occurs with all device types
•	 Healthcare professionals are insufficiently aware of these 
issues
•	 Education can improve:
−	 Inhalation technique
−	 Compliance
−	 Control
•	 Control can also be influenced by:
−	 The device
−	 The formulation
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